Wikidata

(Q66409030)

English

A Phase 3 Study to Evaluate the Efficacy and Safety of Relugolix (TAK-385) 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids

clinical trial

In more languages
default for all languages
No label defined

No description defined

Statements

title
A Multicenter, Randomized, Double-Blind, Parallel-Group, Phase 3 Study to Evaluate the Efficacy and Safety of Oral TAK-385 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids (English)
0 references
medical condition
leiomyoma
0 references
myofibroma
0 references
country
Japan
0 references
start time
5 March 2016
0 references
end time
17 May 2017
0 references
number of participants
281
0 references
minimum age
20 year
0 references

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    Retrieved from "https://www.wikidata.org/w/index.php?title=Q66409030&oldid=2235675238"